RNA methylation: where to from here for hematological malignancies? DOI
Andrew A. Guirguis

Experimental Hematology, Journal Year: 2024, Volume and Issue: 143, P. 104694 - 104694

Published: Dec. 6, 2024

Language: Английский

Recent advances in noncoding RNA modifications of gastrointestinal cancer DOI Creative Commons

Tomoaki Hara,

Sikun Meng,

Yasuko Arao

et al.

Cancer Science, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 1, 2024

Elucidating the mechanisms underlying cancer development and proliferation is important for of therapeutic methods complete cure cancer. In particular, identification diagnostic markers early detection new strategies refractory gastrointestinal cancers are needed. Various abnormal phenomena occur in cells, such as functional changes proteins, led by genomic mutations, gene expression due to dysregulation epigenetic regulation. This no exception noncoding RNA (ncRNA), which do not encode proteins. Recent reports have revealed that microRNA (miRNA), long (lncRNA), circular (circRNA) deeply involved progression. These ncRNAs attracted attention regulatory molecules. advances technology made it possible only read DNA sequences but also study modification state each base. comprehensive analysis N6-methyladenosine (m

Language: Английский

Citations

2
Therapeutic strategies to target the epitranscriptomic machinery DOI Creative Commons
Denise Sighel, Eliana Destefanis, Alessandro Quattrone

et al.

Current Opinion in Genetics & Development, Journal Year: 2024, Volume and Issue: 87, P. 102230 - 102230

Published: July 17, 2024

Altered RNA modification patterns and dysregulated expression of epitranscriptomic machinery proteins (EMPs) have been causatively correlated with several diseases. Modulation EMP gene has shown promise in reversing disease-associated phenotypes, making EMPs attractive therapeutic targets. Various strategies, including small-molecule modulators, proteolysis-targeting chimeras, molecular tools for site-specific engineering modifications, introduced to modulate modifications themselves are currently being investigated enrich the physician's armamentarium. At forefront research inhibitors key players involved N

Language: Английский

Citations

1
Targeting METTL3 protein by proteolysis-targeting chimeras: A novel therapeutic approach for acute myeloid leukemia DOI Creative Commons
Rukiye Nar, Zhixing Wu, Yafang Li

et al.

Genes & Diseases, Journal Year: 2024, Volume and Issue: 12(4), P. 101452 - 101452

Published: Nov. 7, 2024

Language: Английский

Citations

1
Therapeutic approaches targeting oncogenic proteins in myeloid leukemia: challenges and perspectives DOI

Xing Yan,

Yuan Yuan Kang,

Ze Yan Zhang

et al.

Expert Opinion on Therapeutic Targets, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 16, 2024

Leukemia is typically categorized into myeloid leukemia and lymphoblastic based on the origins of leukemic cell. Myeloid a group clonal malignancies characterized by presence increased immature cells in both bone marrow peripheral blood. Of note, aberrant expression specific proteins or generation fusion due to chromosomal abnormalities are well established drivers various forms leukemia. Therefore, these oncoproteins represent promising targets for drug development.

Language: Английский

Citations

1
RNA methylation: where to from here for hematological malignancies? DOI
Andrew A. Guirguis

Experimental Hematology, Journal Year: 2024, Volume and Issue: 143, P. 104694 - 104694

Published: Dec. 6, 2024

Language: Английский

Citations

0